Aphria Inc (TSX: APHA) (NASDAQ: APHA) and AMP German Cannabis Group (CSE: XCX) this morning issued a brief joint press release, outlining that the two firms have partnered up to push sales in Germany. The arrangement has seen the two firms enter a joint marketing agreement for the sale of Aphria branded medical cannabis within the Germany market.
While details were rather slim within the release, it appears that AMP will be utilizing its marketing know-how to push Aphria’s brands through its network. The company has indicated it will begin by organizing what is referred to as information events to market these products to pharmacists and doctors in the region.
AMP has reportedly expanded its sales team to facilitate the agreement, with the two heavily focused on selling the Aphria medical cannabis brand within the country. The agreement is being conducted through Aphria’s wholly-owned subsidiary, CC Pharma.
Financial details of the arrangement were not released.
Aphria Inc last traded at $15.31 on the TSX.
Information for this briefing was found via Sedar and Aphria Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.